| Gene symbol | CXCL12 | Synonyms | IRH, PBSF, SCYB12, SDF1, TLSF, TPAR1 | Type of gene | protein-coding |
| Chromosome | 10 | Map location | 10q11.21 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | C-X-C motif chemokine ligand 12 | ||||
| GTO ID | GTC1736 |
| Trial ID | NCT03168139 |
| Disease | Colorectal Cancer | Pancreatic Cancer |
| Altered gene | CXCL-12 |
| Therapeutic/Target gene | Target gene |
| Therapy | Aptamer |
| Treatment | NOX-A12|olaptesed pegol |
| Phase | Phase1|Phase2 |
| Recruitment status | Completed |
| Title | A Two-part, Open-label Phase 1/2 Study to Evaluate Pharmacodynamic Effects and Safety of Olaptesed Pegol Monotherapy and Safety and Efficacy of Olaptesed Pegol / Pembrolizumab Combination Therapy in Metastatic Colorectal and Pancreatic Cancer |
| Year | 2017 |
| Country | Germany |
| Company sponsor | TME Pharma AG |
| Other ID(s) | SNOXA12C601|2016-003657-15|Keynote-559 |
| Cohort1: NOX-A12 | |||||||
|
|||||||
| Cohort2: NOX-A12_pembrolizumab | |||||||
|
|||||||